1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
PRISM BioLab Co.,LTD

PRISM BioLab Co.,LTD

206A.T
PRISM BioLab Co.,LTDJP flagTokyo Stock Exchange
148.00
JPY
-1.00
- -
5.47BMarket Cap
PRISM BioLab Co.,LTD
206A.T
(Tokyo Stock Exchange)

Recent

price

148.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
FRC
19.09
3.89
9.76
18.54
Revenue per Share
2.51
-18.14
-33.53
-22.82
Basic EPS, GAAP
3.35
-18.88
-1.97
-42.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
1.58
-16.56
5.49
-17.67
Book Value per Share
57.68
39.53
111.9
74.15
Tangible Book Value per Share
29
29
31
37
Basic Weighted Avg Shares
554
113
306
677
Sales/Revenue/Turnover
12.03
-440
-256
-114.34
Operating Margin (%)
1
9
- -
- -
Depreciation Expense
73
-527
-1,050
-834
Net Income, GAAP
1.61
- -
- -
- -
Effective Tax Rate (%)
13.16
-466.6
-343.4
-123.09
Profit Margin (%)
1,667
1,134
3,463
2,669
Working Capital
- -
- -
- -
- -
LT Debt
1,675
1,148
3,503
2,709
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-22.67%
Free Cash Flow
- -
- -
2,395.49%
Net Income, GAAP
- -
- -
-20.56%
Sales/Revenue/Turnover
- -
- -
121.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
306
2025
- -
- -
- -
- -
677
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-33.53
2025
- -
- -
- -
- -
-22.82
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Zeo ScientifiX, Inc. (ZEOX)
Beijing Kawin Technology Share-Holding Co., Ltd. (688687.SS)
AVEO Pharmaceuticals, Inc. (AVEO)
Crinetics Pharmaceuticals, Inc. (CRNX)
Immunic, Inc. (IMUX)
Advicenne S.A. (ALDVI.PA)
Business
PRISM BioLab Co., Ltd. (206A.T) develops small molecule inhibitors targeting protein-protein interactions using its proprietary PepMetics technology platform, which generates orally available compounds mimicking alpha-helix and beta-turn peptides to address undruggable targets in oncology, autoimmune diseases, fibrosis, and other indications; the PepMetics library comprises over 20,000 compounds for screening difficult therapeutic areas. Core pipeline assets include E7386, a CBP/beta-catenin inhibitor co-developed with Eisai Co., Ltd. in Phase II trials for cancer, and PRI-724, also targeting CBP/beta-catenin, advancing in Phase II for cirrhosis under license to Ohara Pharmaceutical Co., Ltd., alongside seed compounds for novel bicyclic PepMetics. Founded in 2006 and headquartered in Fujisawa, Japan, with a Tokyo office, the company operates primarily in Japan and pursues global collaborations. Recent developments encompass achievement of an initial milestone and receipt of upfront payment from Ono Pharmaceutical Co., Ltd. in a November 2025 drug discovery alliance for oncology targets; a new April 2025 partnership with Elix, Inc. to integrate AI-driven design into PepMetics research; patent grants in 2025 for novel bicyclic PepMetics compounds and library technologies; initiation of patient enrollment in a Phase I drug-drug interaction study for PRI-724; terminations of prior collaborations with Servier and Eli Lilly in 2025; a 1.5 billion yen Series C funding round in January 2024; and recruitment of key scientific talent in 2025 to bolster medicinal chemistry and translational pharmacology capabilities.